Federal Bureau of Investigation seeks to thwart cyber-attack on Ukraine
Service dog unexpectedly gives birth at Florida airport
NTSB's preliminary report on Uber crash focuses on emergency braking
Fiat Chrysler recalls almost 5 million cars over cruise control problem
S. Korea says Moon met N. Korea’s Kim in DMZ
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Downgraded by Morgan Stanley
17 July 2017, 08:37 | Kelvin Horton
On 07/13/2017 close, OcularTherapeutix, Inc. Morgan Stanley lowered shares of OcularTherapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a research note on Friday, June 23rd. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company's stock worth $103,000 after buying an additional 844 shares during the last quarter.
A number of brokerages have recently weighed in on OCUL. The other 3, though not evenly; between analysts who think you should buy OcularTherapeutix, Inc. versus those who think you should sell it. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $27.00 on company shares. The firm has "Overweight" rating by Cantor Fitzgerald given on Friday, February 10. They now have a Dollars 21 price target on the stock. The stock experienced -4.88% slump, arriving at $6.33 on Jul. 14, 2017. In contrast, the average volume was 1.37 million shares. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -30.31% where SMA50 and SMA200 are -32.26% and -22% respectively. OcularTherapeutix has a one year low of $4.04 and a one year high of $11.91. The stock's market capitalization is $178.52 million.
OcularTherapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Friday, May 5th. The company maintains price to book ratio of 2.15 vs.an industry average at 1.27. It has a return on equity (ROE) of -80.20%. The firm had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.51 million. (OCUL) is -0.58 while the analysts predicted the EPS of the stock to be -0.48 suggesting the company fell short of the analysts' expectations. On average, equities analysts expect that OcularTherapeutix will post ($2.25) EPS for the current fiscal year. The correct version of this article can be viewed at https://www.com-unik.info/2017/07/17/fy2017-eps-estimates-for-ocular-therapeutix-inc-lifted-by-cantor-fitzgerald-nasdaqocul.html. Cantor Fitzgerald now has a "Overweight" rating and a $21.00 target price on the stock. If you are reading this news story on another website, it was stolen and reposted in violation of global trademark & copyright laws. About shares traded. OcularTherapeutix Inc (NASDAQ:OCUL) has declined 9.50% since July 17, 2016 and is downtrending.
Institutional investors have recently added to or reduced their stakes in the company.
ILLEGAL ACTIVITY WARNING: "49,024 Shares in OcularTherapeutix, Inc".
A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. Berson & Corrado Investment Advisors LLC increased its stake in OcularTherapeutix by 5.8% in the first quarter. Columbus Circle Investors boosted its stake in OcularTherapeutix by 131.4% in the first quarter. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company's stock worth $3,705,000 after buying an additional 284,200 shares during the period. Finally, Trexquant Investment LP bought a new position in shares of OcularTherapeutix during the fourth quarter valued at about $181,000.
Institutional investors now hold around $122 million or 63.9% in OCUL stock.
Taking a look back at some historical performance numbers for OcularTherapeutix, Inc. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.
Rouhani's brother arrested on financial charges: Judiciary
Also, Karan Vafadari, who owns an art gallery in Tehran , was arrested last July with his wife, who is a permanent US resident. A Chinese-born American researcher has been awarded 10 years of imprisonment after being convicted of spying in Iran .
DHS Approves 15000 Additional Temporary Worker Visas
To receive the visas, businesses must attest they would suffer irreparable harm if they can not bring in those workers. The administration insisted the visa boost is not incompatible with its "America first" pledge.
Troops On Offensive To Re-Take Helmand's Nawa District
The security forces plan to continue the operation southward along the main road to the town of Garmsir, officials said. The Afghan government said Monday that troops retook a key district in the southern Helmand province from the Taliban.
Jay-Z Snags His 14th No. Album with '4:44'
The album, Jay-Z's first in four years, won favorable reviews and marked growing introspection from the 47-year-old rapper. Ever since Vol. 2.Hard Knock Life which came out in 1998, every one of Hov's solo efforts have reached the top spot.